Elon Musk claims he turned down 'several high-paid jobs' on Wall Street. He's now worth $187 billion and is the world's second-richest person.
Elon Musksaid Monday that he rejected multiple 'high-paid' Wall Streetjobs, Bloomberg reported.
- Musk didn't say when he rejected the jobs, or which companies tried to hire him.
- Musk made the remarks as part of a court case into
Tesla's acquisition of SolarCity.
Tesla CEO Elon Musk claims he rejected "several" lucrative jobs on Wall Street to instead focus on the booming
"I was offered several high-paid jobs on Wall Street," Musk told a court in Delaware on Monday, per a report by Bloomberg. "I declined."
He didn't elaborate on what the roles were, or which companies tried to hire him.
Musk made the remarks as part of a court case into Tesla's 2016 acquisition of solar panel firm SolarCity. The company's shareholders sued him and other Tesla board members in 2017, claiming Tesla effectively bailed out SolarCity, which was founded by two of Musk's cousins.
Every Tesla board member named in the suit other than Musk settled for $60 million in January 2020.
Rather than getting into
Musk is the CEO of automaker Tesla and aerospace giant
Both the tech and finance industries are known for long working weeks and high rates of burnout. Musk has previously said he works between 85 to 100 hours each week , and has to split his day into five-minute slots so he can fit everything in.
He said at Monday's hearing that he "hates" being the CEO of Tesla and would rather spend his time on design and engineering.
- A college is removing its vending machines after a student discovered they were using facial-recognition technology
- 11 states pay more in federal taxes than they get back - here's how every state fares
- Steve Jobs once said the best managers are 'individual contributors' who aren't interested in managing people
- Fuel your morning: Wholesome South Indian breakfast ideas for health
- Vodafone Idea shares tumble 14%, mcap erodes ₹10,806.7 cr
- National parties declare income of ₹3,077 cr in 2022-23; BJP has highest share
- Human trials may reveal efficacy of new Rs 100 cancer pill: Docs
- Multiplexes' revenue growth to dip to 15% in FY25 as OTTs crimp profit margins